Idenix Seeks $2.5B In Gilead Hep C Drug Patent Dispute
Idenix Pharmaceuticals LLC told a federal jury in Delaware Monday that it wants more than $2.5 billion from Gilead Sciences Inc. as compensation for a patent infringement "betrayal" that allegedly laid...To view the full article, register now.
Already a subscriber? Click here to view full article